<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Insulin therapy in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) can produce greater improvements in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) and glycated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbA1c) than oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs (OADs) </plain></SENT>
<SENT sid="1" pm="."><plain>There is a growing trend to recommend initiation of insulin in T2DM patients sooner in the course of the disease, and good results have been achieved in insulin-naïve patients during randomised, controlled trials, often using aggressive dose titration algorithms </plain></SENT>
<SENT sid="2" pm="."><plain>The Physicians' Routine Evaluation of Safety &amp; Efficacy NovoMix((R)) 30 Therapy (PRESENT) study was a 6-month observational study of the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) as monotherapy or in combination with OADs in inadequately controlled patients with T2DM </plain></SENT>
<SENT sid="3" pm="."><plain>This review article compares results from those patients who entered the study insulin-naïve (either with or without previous OAD treatment), with results from randomised, controlled trials of BIAsp 30 in insulin-naïve T2DM patients </plain></SENT>
<SENT sid="4" pm="."><plain>It aims to provide guidance on the initiation of insulin in patients with T2DM, focusing on the efficacy of BIAsp 30 when used for this purpose, and highlighting both the low risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> associated with therapy, and the availability of delivery devices that can minimise injection site discomfort and help to overcome psychological <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
</text></document>